Chemical industry – Page 54
-
BusinessDuPont settles fluorinated chemical lawsuits
DuPont and spinoff Chemours will pay more than $670m to settle around 3500 personal injury claims relating to PFOA exposure
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessDaiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
-
BusinessUS biotech leaders protest immigration ban
Donald Trump’s suspended order would endanger America’s biotech industry if re-instated
-
BusinessFatal liquid nitrogen release at US sperm bank
Workplace safety agency to probe death of deputy sheriff after apparent asphyxiation at Xytex in Augusta
-
BusinessSabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
-
OpinionHow much is your chief executive worth?
The executive pay and equality debate is here to stay
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
OpinionDrug regulation is a burden worth bearing
Calls to break down regulatory barriers show a misunderstanding of the industry
-
PodcastAdamantane
Brian Clegg introduces a crystalline hydrocarbon that isn’t as tough as it sounds, but is the basis of a wide range of medicines
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
BusinessOpening doors to innovation
Chemical companies are increasingly using specialist investment arms to nurture new ideas
-
ResearchDrug binding simulations promise to get personal
Fast, reliable new molecular dynamic simulation methods set to speed up research are under investigation by GSK
-
BusinessUS Supreme Court denies Dow tax appeal
Request to reconsider $1bn tax deduction dismissed and penalties upheld
-
NewsVolkswagen hit by another $4.3bn in penalties
Emissions cheating scandal has led to the arrest of six senior employees at the company, just as Fiat comes under fire
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation